SCHEDULE: BlackRock Discloses 6.0% Stake in Verastem Inc.
Beneficial Ownership Report
BlackRock, Inc. has reported a 6.0% beneficial ownership stake in Verastem Inc., holding 3,676,905 shares of common stock.
Summary
- BlackRock, Inc. reported beneficial ownership of 3,676,905 shares of Verastem Inc. common stock.
- This represents 6.0% of Verastem Inc.'s outstanding common stock.
- BlackRock holds sole voting power over 3,609,080 shares and sole dispositive power over 3,676,905 shares.
- The filing was made by BlackRock, Inc. as a parent holding company, with several subsidiaries identified as beneficially owning 5% or greater of the outstanding shares.
- The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Verastem Inc.
- The date of the event which required this filing is 09/30/2025.
Sentiment
Score: 7
Explanation: The filing indicates a significant institutional investment by BlackRock, suggesting a positive long-term view from a major asset manager, without any intent to influence control, which is generally seen as a stable investment.
Positives
- A major institutional investor, BlackRock, holds a significant 6.0% stake, indicating potential confidence in Verastem Inc.'s long-term prospects.
- The holding is for investment purposes in the ordinary course of business, not for activist control, suggesting a stable, passive investment.
Negatives
- NA
Risks
- NA
Future Outlook
NA
Management Comments
- The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.
Industry Context
This filing indicates a significant institutional investment in Verastem Inc., a company likely operating in the biotechnology or pharmaceutical sector. Such investments by large asset managers like BlackRock are common and reflect their portfolio management strategies across various industries, often signaling a belief in the company's long-term value proposition.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Update | BlackRock, Inc. updated its Power of Attorney, revoking the previous one dated April 30, 2023, and appointing new attorneys-in-fact for SEC and other regulatory filings. | 2025-01-21 | Streamlines BlackRock's internal compliance and filing processes, but has no direct impact on Verastem Inc.'s corporate governance. |
Stakeholder Impact
- Shareholders: Increased confidence due to significant institutional investment by BlackRock.
- Management: No immediate direct impact, but a large institutional holder may imply increased scrutiny or engagement over time.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Previous Power of Attorney revoked by BlackRock, Inc. |
| 2025-01-21 | Effective date of the new Power of Attorney for BlackRock, Inc. |
| 2025-09-30 | Date of event which requires filing of this statement. |
| 2025-10-17 | Signature date of the Schedule 13G filing by BlackRock, Inc. |
Recommendation
holdBlackRock's disclosure of a 6.0% beneficial ownership in Verastem Inc. indicates a significant institutional investment, which can be a positive signal for the company's long-term prospects. However, this filing alone does not provide sufficient operational or financial details to warrant a 'buy' or 'sell' recommendation. Investors should 'hold' and monitor further developments, considering this institutional backing as a potentially stabilizing factor.
Keywords
Verastem Inc., BlackRock, Institutional Ownership, Common Stock, SEC Filing, Schedule 13G, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.